A ROLE FOR INFLAMMATORY IL-6 IN THE DEVELOPMENT OF CORONARY ARTERY DISEASE: A CASE CONTROL STUDY AT AL-QADISIYAH GOVERNORATE, IRAQ
Q3 Pharmacology, Toxicology and Pharmaceutics
Ajil A. Alzamily, Mohammed N. Al-Delfi, Aqeel R Al-Barqaw
{"title":"A ROLE FOR INFLAMMATORY IL-6 IN THE DEVELOPMENT OF CORONARY ARTERY DISEASE: A CASE CONTROL STUDY AT AL-QADISIYAH GOVERNORATE, IRAQ","authors":"Ajil A. Alzamily, Mohammed N. Al-Delfi, Aqeel R Al-Barqaw","doi":"10.31482/mmsl.2022.005","DOIUrl":null,"url":null,"abstract":"Background: Disruption of the IL-6 axis can result in the beginning or progression of a variety of disease states, including cardiovascular diseases. Because of IL-6's pathogenic function, pharmacologic manipulation of the IL-6 axis is a sensible therapeutic strategy;nevertheless, various expected, yet frequently overlooked, effects on tissues and organs other than blood vessels may also occur. The study's goal is as follows: The purpose of this study is to see how inflammatory Interleukin-6 affects the development of coronary artery disease. Materials and Methods: Serum IL-6 level was estimated using Elabscience® kits. A case-control study included 30 CAD patients, 30 positive controls (PC) [(have family history for CAD)], and 30 negative controls (NG) [they have no family history for CAD]. Ranged from 30 to 81 years old. Patients with acute or chronic illnesses such as liver disease, renal disease, thyroid function disorders, COVID-19, and autoimmune disease were excluded from the study. During the period from December 2020 to May 2021. Our study was included other factors such as ages, genders, smoking, family history, antihypertensive drugs or drugs for other diseases, body mass index (BMI) which were assessed. Results: The results of this study show increased levels of IL-6 in patients with CAD compared with the PC and NC These results showed a highly significant difference (p < 0.0001) in the concentrations compared with PC and NC. Conclusions: IL-6 could be one of the prognostic signs of CAD. © 2022, University of Defence, Faculty of Military Health Sciences. All rights reserved.","PeriodicalId":38749,"journal":{"name":"Vojenske Zdravotnicke Listy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vojenske Zdravotnicke Listy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31482/mmsl.2022.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3
Abstract
Background: Disruption of the IL-6 axis can result in the beginning or progression of a variety of disease states, including cardiovascular diseases. Because of IL-6's pathogenic function, pharmacologic manipulation of the IL-6 axis is a sensible therapeutic strategy;nevertheless, various expected, yet frequently overlooked, effects on tissues and organs other than blood vessels may also occur. The study's goal is as follows: The purpose of this study is to see how inflammatory Interleukin-6 affects the development of coronary artery disease. Materials and Methods: Serum IL-6 level was estimated using Elabscience® kits. A case-control study included 30 CAD patients, 30 positive controls (PC) [(have family history for CAD)], and 30 negative controls (NG) [they have no family history for CAD]. Ranged from 30 to 81 years old. Patients with acute or chronic illnesses such as liver disease, renal disease, thyroid function disorders, COVID-19, and autoimmune disease were excluded from the study. During the period from December 2020 to May 2021. Our study was included other factors such as ages, genders, smoking, family history, antihypertensive drugs or drugs for other diseases, body mass index (BMI) which were assessed. Results: The results of this study show increased levels of IL-6 in patients with CAD compared with the PC and NC These results showed a highly significant difference (p < 0.0001) in the concentrations compared with PC and NC. Conclusions: IL-6 could be one of the prognostic signs of CAD. © 2022, University of Defence, Faculty of Military Health Sciences. All rights reserved.
炎症性IL-6在冠状动脉疾病发展中的作用:伊拉克AL-QADISIYAH省的病例对照研究
背景:IL-6轴的破坏可导致多种疾病状态的开始或进展,包括心血管疾病。由于IL-6的致病功能,对IL-6轴的药理学操作是一种明智的治疗策略;然而,对血管以外的组织和器官也可能产生各种预期但经常被忽视的影响。这项研究的目标如下:本研究的目的是观察炎症性白细胞介素-6如何影响冠状动脉疾病的发展。材料和方法:使用Elabscience®试剂盒评估血清IL-6水平。一项病例对照研究包括30名CAD患者、30名阳性对照(PC)[(有CAD家族史)]和30名阴性对照(NG)[他们没有CAD家族史]。年龄从30岁到81岁不等。患有肝病、肾病、甲状腺功能紊乱、新冠肺炎和自身免疫性疾病等急性或慢性疾病的患者被排除在研究之外。2020年12月至2021年5月期间。我们的研究包括其他因素,如年龄、性别、吸烟、家族史、抗高血压药物或其他疾病药物、评估的体重指数(BMI)。结果:本研究结果显示,与PC和NC相比,CAD患者的IL-6水平升高。这些结果显示,IL-6浓度与PC和数控相比有非常显著的差异(p<0.0001)。结论:IL-6可能是CAD的预后标志之一。©2022,国防大学军事卫生科学学院。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。